Complete remission of metastatic malignant melanoma treated with nivolumab, complicated with pulmonary toxicity

Abstract

Immunotherapy is the basic therapeutic approach for patients with metastatic malignant melanoma. This therapy improves overal survival and might achieve long lasting complete remissions or stabilizations.

One of the pitfalls of this innovative therapy is its toxicity. The following case report describes patient treated with nivolumab for metastatic malignant melanoma with a complete therapeutic response, but with the development of recurrent lung toxicity.

Keywords

• melanoma
• toxicity
• nivolumab
• immunotherapy